

Thoracic Disease-Oriented Team

Clinical Research Treatment Flowchart



ADVANCED/METASTATIC

Open to Accrual

Low Accruing

Pending Activation

1L

UCI 24-192 (Nuvalent)

NVL-655 vs Alectinib

Mechanism: ALK inhibitor
Coord: Mindy Chen
PI: Dr. Nagasaka
Accrual: 1/5

2L

UCI 21-241 (Nuvalent)

NVL-655 + ALK inhibitor

Mechanism: ALK
Inhibitor
Coord: Keagan Buttigieg
PI: Dr. Nagasaka
Accrual: 20/25

UCI 25-51 (Nuvalent)

NVL-655 EAP

Mechanism: ALK
inhibitor
Coord: Mindy Chen
PI: Dr. Park
Accrual: 15/20

UCI 25-189 (Astellas)

Mechanism: ALK
inhibitor
Coord: Richard Chang
PI: Dr. Arter
Accrual: 0/5

UCI 26-23 (Triana
Biomedicines)

Mechanism: ALK
inhibitor
Coord: To be
determined
PI: Dr. Nagasaka
Accrual: 0/10



ADVANCED/METASTATIC

Exon 18

1L

UCI 24-169
(BlossomHill
Therapeutics)
BH-30643 Capsule

Mechanism: EGFR or
HER2 TKI
Coord: Celest Ramirez
PI: Dr. Nagasaka
Accrual: 11/15

2L

■ Open to Accrual

■ Low Accruing

■ Pending Activation

Exon 19 del or L858R

UCI 24-169
(BlossomHill
Therapeutics)
BH-30643
Capsule

Mechanism:
EGFR or
HER2 TKI
Coord: Celest
Ramirez
PI: Dr.
Nagasaka
Accrual: 12/15

UCI 24-181
(Janssen
Research &
Development)
Amivantamab +
Lazertinib
Mechanism:
EGFR TKI
Coord:
Stephanie
Fernandez
PI: Dr. Park
Accrual: 4/10

UCI 23-178
BL-B01D1 IV

Mechanism:
EGFR and/or
HER3 bispecific
antibody
Coord: Cassie
Smith
PI: Dr. Park
Accrual: 5/10

UCI 22-217
(Janssen)
Amivantamb +
Lazertinib w/ or
without Carbo +
Pemetrexed

Mechanism:
Antibody drug w/
TKI and Chemo
Coord: Richard
Chang
PI: Dr. Nagasaka
Accrual: 5/15

UCI 25-80
(AstraZeneca/TROPION-
Lung14)
Osimertinib +/- Dato-DXd

Mechanism: TKI +/- ADC
Coord: TBD
PI: Dr. Nagasaka
Accrual: 0/5

UCI 25-187
(BMS/IZABRIGHT-Lung01)
Iza-Bren vs platinum based
chemo + pemetrexed

Mechanism: ADC
Coord: TBD
PI: Dr. Nagasaka
Accrual: 0/5



Exon 20

Exon 21

1L

UCI 22-217(Janssen)Amivantamb + Lazertinib w/ or
without Carbo + PemetrexedMechanism: Antibody drug w/ TKI
and Chemo
Coord: Richard Chang
PI: Dr. Nagasaka
Accrual: 5/15UCI 24-169
(BlossomHill
Therapeutics)

BH-30643 Capsule

Mechanism: EGFR
or HER2 TKI
Coord: Celest
Ramirez
PI: Dr. Nagasaka
Accrual: 12/15UCI 24-169
(BlossomHill
Therapeutics)

BH-30643 Capsule

Mechanism:
EGFR or HER2 TKI
Coord: Celest
Ramirez
PI: Dr. Nagasaka
Accrual: 12/15UCI 24-181 (Janssen Research
& Development)Amivantamab + Lazertinib
Mechanism: EGFR TKI
Coord: Stephanie Fernandez
PI: Dr. Park
Accrual: 4/10

2L



Exon 20 / Uncommon and Compounded Mutations

1L

UCI 26-10 (UCLA/L-13)

Zipalertinib with Carboplatin +
Pemetrexed

Mechanism: TKI + Chemo

Coord: TBD

PI: Dr. Arter

Accrual: 0/5

2L



ADVANCED/METASTATIC

1L

2L

Exon 18

Exon 19

Exon 20

Exon 21

UCI 24-169 (BlossomHill Therapeutics)

BH-30643 Capsule

Mechanism: EGFR or HER2 TKI

Coord: Celest Ramirez

PI: Dr. Nagasaka

Accrual: 12/15

UCI 23-178

BL-B01D1 IV

Mechanism: EGFR and/or HER3 bispecific antibody

Coord: Cassie Smith

PI: Dr. Park

Accrual: 5/10



Early Stage

 Open to Accrual

 Low Accruing

 Pending Activation

UCI 25-79 (Beamion Lung-3)

Zongertinib vs SOC
(Adjuvant therapy)

Mechanism: TKI
Coord: To be determined
PI: Dr. Arter
Accrual: 0/3

KRAS G12C

G12A, G12D, G12R, G12S, G12V (Cont.)

1L

UCI 22-30 (D3S-001-100):
D3 Bio

Mechanism: TKI
Coord: Cassie Smith
PI: Dr. Nagasaka
Accrual: 5/8

UCI 25-88 (Part A:
Olomorasib w/ Pembro or
Placebo w/ Pembro. Part B:
Durvalumab w/ Pembro or
Placebo w/ Durvalumab)

Mechanism: TKI and Anti-
PD-1 / Anti-PD-L1
Coord: TBD
PI: Dr. Park
Accrual: 0/5

UCI 25-164: Divarasib
+ Pembro vs Pembro +
Pem + Carbo or
Cisplatin

Mechanism: TKI +
Immuno + Chemo
Coord: TBD
PI: Dr. Nagasaka
Accrual: 0/5

2L

UCI 23-116 (RMC-6291
Revolution Medicine)

Mechanism: TKI
Coordinator: Richard
Chang
PI: Dr. Arter
Accrual: 1/10

UCI 25-162: BBO-
8520(The ONKORAS-
101

Mechanism: TKI
Coord: TBD
PI: Dr. Arter
Accrual: 0/5

UCI 24-157 (RMC-6236-301)
RMC-6236 vs Docetaxel

Mechanism: TKI
Coord: To be determined
PI: Dr. Arter
Accrual: 0/5

UCI 22-87 (RMC-6236
Revolution Med)

Mechanism: TKI
Coordinator: Jenny Choe
PI: Dr. Arter
Accrual: 43/50



ADVANCED/METASTATIC

 Open to Accrual

 Low Accruing

 Pending Activation

G12C, G12V, G12D

1L

2L

UCI 25-163
(TBBO11818-101)

Mechanism: TKI
Coord: TBD
PI: Dr. Arter
Accrual: 0/5

ADVANCED/METASTATIC

NTRK 1-3

Open to Accrual

Low Accruing

Pending Activation

1L

2L



ADVANCED/METASTATIC



Open to Accrual



Low Accruing



Pending Activation



ADVANCED/METASTATIC



Open to Accrual



Low Accruing



Pending Activation

ROS1

1L

2L

UCI 21-47 (NVL-520 Nuvalent)

Mechanism: TKI
Coord: Keagan Buttigieg
PI: Dr. Nagasaka
Accrual: 11/16

Early Stage

UCI 24-196 (Nuvation)

Taletrectinib vs Placebo post
complete resection
(Adjuvant therapy)

Mechanism: ROS1 inhibitor
Coord: Stephanie Fernandez
PI: Dr. Arter
Accrual: 0/5

 Open to Accrual Low Accruing Pending Activation



■ Open to Accrual

■ Low Accruing

■ Pending Activation

Advanced / Metastatic

1L

UCI 24-83: CB-NK +
Atezolizumab

Mechanism: PD-L1
Coord: TBD
PI: Dr. Villalona
Accrual: 0/9

UCI 25-114: Ivonescimab vs
Pembrolizumab (High PD-L1
Expression (TPS> 50%))

Mechanism: PD-L1
Coord: Richard Chang
PI: Dr. Park
Accrual: 0/5

UCI 24-195 (Seagen/Pfizer):
PF-08046054/SGN-PDL1V

Mechanism: PD-L1
Coord: Jenny Choe
PI: Dr. Nagasaka
Accrual: 0/5

2L

UCI 25-101 UCLA/Summit
Therapeutics: Thymic
Cancer (Ivonescimab)

Mechanism: PD-L1
Coord: TBD
PI: Dr. Arter
Accrual: 0/5

UCI 25-227 (Fortvita
Biologics): IBI363 +/- SOC
therapy

Mechanism: PD-L1
Coord: TBD
PI: Dr. Arter
Accrual: 0/5



 Open to Accrual

 Low Accruing

 Pending Activation

UCI 24-197 (TNG456
Monotherapy & Combo w/
Abemaciclib)

Mechanism:
Coord: Cassie Smith
PI: Dr. Park
Accrual: 1/5



 Open to Accrual

 Low Accruing

 Pending Activation

UCI 24-138 (UCLA):
Tarlatamab

Mechanism: BiTE molecule
Coord: Cassie Smith
PI: Dr. Park
Accrual: 2/5

UCI 25-133: (ZG006)

Mechanism: BiTE molecule
Coord: Jenny Choe
PI: Dr. Arter
Accrual: 2/5



 Open to Accrual

 Low Accruing

 Pending Activation

UCI 25-194 (Plexium)

PLX-61639

Mechanism: SMARCA2

Degrader

Coord: TBD

PI: Dr. Villalona

Accrual: 0/5



 Open to Accrual

 Low Accruing

 Pending Activation

Adjuvant

ADVANCED/METASTATIC

UCI 25-89 (IBI3009)

Mechanism: Recombinant Anti-DLL3
Monoclonal Antibody-Camptothecin
Derivative Conjugate for Injection

Coodinator: TBD
PI: Dr. Arter

Accrual: 0/5

 Open to Accrual

 Low Accruing

 Pending Activation

UCI 22-86: Gut Microbiome Study

Mechanism: Fecal Collection
 Coord: Stephanie Fernandez
 PI: Dr. Nagasaka
 Accrual: 11/82

UCI 24-118 (Keshava IIT): Lung Cancer Family Screening

Mechanism: NA
 Coord: Stephanie Fernandez/
 Mindy Chen
 PI: Dr. Keshava
 Accrual: 51/1753

UCI 25-179 (T. Waddington IIT)
 Optical Coherence Tomography (OCT) w/ Robotic assisted
 bronch evaluate peripheral
 nodes

Mechanism: N/A
 CRC: TBD
 PI: Dr. Waddington
 Accrual: 0/5

UCI 25-191 (Nagasaka IIT)

Mechanism: N/A
 CRC: TBD
 PI: Dr. Nagasaka
 Accrual: 0/25

UCI 24-87 (Arter IIT): Methionine-Reduced Diet

Mechanism: N/A
 CRC: TBD
 PI: Dr. Arter
 Accrual: 2/25

UCI 23-155:
 Chatbot for Online Support
 Groups to Treat Tobacco
 Addiction

Mechanism: N/A
 CRC: TBD
 PI: Dr. Pechmann
 Accrual: 0/126



 Open to Accrual

 Low Accruing

 Pending Activation

Advanced / Metastatic

1L

UCI 24-113 (BMS-986482)
Bristol-Myers Squibb

Mechanism: PDL1
Coord: Natalie Arechiga
PI: Dr. Chow
Accrual: 5/10

2L

UCI 24-08 (SPEDOX-6): Dr.
Chow IIT

Mechanism: SPE
Coord: Erin Palmer-Torrison
PI: Dr. Chow
Accrual: 8/67

UCI 25-75 (CRN09682-191):
Crinetics Pharmaceuticals

Mechanism: NDC
Coord: Michelle Andrade
PI: Dr. Dayyani
Accrual: 0/15